share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  08/12 17:02

Moomoo AI 已提取核心訊息

180 Life Sciences Corp. reported its financial performance for the quarter ended June 30, 2024, with a net income of $11,781, a significant improvement from the net loss of $3,680,169 in the same period the previous year. This turnaround was primarily due to other income of $1,858,519, including $1,712,702 from insurance proceeds. Research and development expenses decreased by 38% to $488,323, while general and administrative expenses also saw a significant reduction of 56% to $1,224,750. The company's business development has been focused on its three product development platforms: fibrosis and anti-TNF, drugs derived from CBD or CBG analogues, and α7nAChR. However, due to limited resources, activities in the SCA and anti-TNF platforms have slowed, and the α7nAChR program has been suspended. Future plans include evaluating options to monetize existing assets and exploring strategic alternatives to maximize shareholder value, which may include mergers, acquisitions, asset sales, licensing, or other transactions.
180 Life Sciences Corp. reported its financial performance for the quarter ended June 30, 2024, with a net income of $11,781, a significant improvement from the net loss of $3,680,169 in the same period the previous year. This turnaround was primarily due to other income of $1,858,519, including $1,712,702 from insurance proceeds. Research and development expenses decreased by 38% to $488,323, while general and administrative expenses also saw a significant reduction of 56% to $1,224,750. The company's business development has been focused on its three product development platforms: fibrosis and anti-TNF, drugs derived from CBD or CBG analogues, and α7nAChR. However, due to limited resources, activities in the SCA and anti-TNF platforms have slowed, and the α7nAChR program has been suspended. Future plans include evaluating options to monetize existing assets and exploring strategic alternatives to maximize shareholder value, which may include mergers, acquisitions, asset sales, licensing, or other transactions.
180 Life Sciences Corp.報告了截至2024年6月30日的財務表現，淨利潤爲11,781美元，相比前年同期淨虧損3,680,169美元，有了顯著的改善。這一轉變主要歸因於其他收入1,858,519美元，其中包括保險賠償金1,712,702美元。研發費用減少了38%，爲488,323美元，而總管理費用也大幅減少了56%，爲1,224,750美元。公司業務發展集中在三個產品開發平台上：纖維化和抗TNF，基於CBD或CBG類似物的藥物，以及α7nAChR。然而，由於資源有限，SCA和抗TNF平台的活動已經減緩，α7nAChR計劃已經暫停。未來計劃包括評估獲利現有資產的選擇，探索最大化股東價值的戰略選擇，其中可能包括併購、資產銷售、許可證或其他交易。
180 Life Sciences Corp.報告了截至2024年6月30日的財務表現，淨利潤爲11,781美元，相比前年同期淨虧損3,680,169美元，有了顯著的改善。這一轉變主要歸因於其他收入1,858,519美元，其中包括保險賠償金1,712,702美元。研發費用減少了38%，爲488,323美元，而總管理費用也大幅減少了56%，爲1,224,750美元。公司業務發展集中在三個產品開發平台上：纖維化和抗TNF，基於CBD或CBG類似物的藥物，以及α7nAChR。然而，由於資源有限，SCA和抗TNF平台的活動已經減緩，α7nAChR計劃已經暫停。未來計劃包括評估獲利現有資產的選擇，探索最大化股東價值的戰略選擇，其中可能包括併購、資產銷售、許可證或其他交易。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間